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Background: Immune checkpoint inhibitors have been tried for several thoracic malignancies; however, 
their application as a neoadjuvant therapy in esophageal squamous cell carcinoma (ESCC) has not been 
studied. We evaluated the feasibility and safety of esophagectomy and total lymphadenectomy after 
neoadjuvant chemoradiation therapy with pembrolizumab.
Methods: Between 2017 and 2018, 38 patients who received the neoadjuvant therapy followed by radical 
esophagectomy and total lymphadenectomy for ESCC were analyzed. Twenty-two patients received 
conventional neoadjuvant chemoradiation therapy (Group 1), and sixteen patients received neoadjuvant 
chemoradiation therapy with pembrolizumab in clinical trial (Group 2). Two groups were compared 
retrospectively. 
Results: The basic characteristics of age, clinical stage, location and methods of operation were not 
different between the two groups. The pathologic stages were higher in Group 2, but the difference was not 
statistically significant. The operative outcomes, i.e., operation time, blood loss, and numbers of dissected 
lymph nodes in the thorax, neck, and abdomen were comparable. Complications, including pulmonary 
complications and anastomotic leakage, were also comparable. The rate of recurrent laryngeal nerve palsy 
was also comparable between the two groups (31.8% vs. 18.8%, P=0.469). Operative mortalities developed in 
2 patients [0 vs. 2 (12.5%), P=0.171] due to acute respiratory distress syndrome (ARDS). 
Conclusions: Radical esophagectomy for esophageal squamous cell carcinoma after neoadjuvant 
chemoradiation therapy with pembrolizumab may not increase the operative risk or reduce the quality 
of radical dissection including lymphadenectomy. The risk of ARDS after neoadjuvant neoadjuvant 
chemoradiation therapy with pembrolizumab has to be studied in the further analysis.
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Introduction
The mainstay of treatment for esophageal squamous 
cell carcinoma (ESCC) includes surgical treatment, 
chemotherapy,  and radiotherapy,  and it  has been 
reported that multidisciplinary treatment combining 
these three modalities is most effective (1). Although the 
improvement of surgical technique and chemoradiation 
(CCRTx) strategies for ESCC have been achieved, the 
survival of esophageal cancer after multimodality therapy 
and esophagectomy still remains low; the 5-year overall 
survival of ypStage I and ypStage II are about 50% and 
30%, respectively, in the Worldwide Esophageal Cancer 
Collaboration (WECC) data (2). Therefore, developing 
novel therapeutic strategies in addition to the conventional 
strategies is urgently needed to improve long-term 
survival. 
Recent breakthrough results from immune checkpoint 
inhibitors such as an anti-cytotoxic T-lymphocyte-
associated protein 4 (CTLA4) antibody (ipilimumab) and 
anti-programmed death 1 (PD-1) antibody have paved 
the way for a new era of cancer immunotherapy, leading 
to paradigm shift in cancer treatment (3). In ESCC, 
the results of the clinical trials using anti-PD1 antibody 
(nivolumab and pembrolizumab) in advanced stage were 
promising (4). Because the immunotherapy for the other 
thoracic malignancies, such as non-small cell lung cancer, 
have been studied extensively not only for the advanced 
and unresectable stages but also for the neoadjuvant 
setting in resectable disease, immunotherapy for ESCC 
could also be tried in the neoadjuvant setting. In addition, 
perioperative safety and the risk of serious adverse events 
after esophagectomy have not been adequately addressed 
even though the number of indications and patients on 
trials being treated with immunotherapy has increased. 
Especially, esophagectomy is an invasive procedure in 
oncologic surgery with high morbidities and mortalities, 
and there are no previous studies evaluating the safety 
and feasibility of radical esophagectomy after neoadjuvant 
immunotherapy followed by esophagectomy. Therefore, 
the purpose of this retrospective study was to evaluate 
the safety and feasibility of radical esophagectomy after 
neoadjuvant immunotherapy. We present the following 
article in accordance with the STROBE reporting 
checklist (available at http://dx.doi.org/10.21037/jtd-20-
1088). 
Methods
Study data and patient selection 
This study conformed to the provisions of the Declaration 
of Helsinki (as revised in 2013). This retrospective study 
was approved by the Institutional Review Board (2019-
1950-001) and the informed consents were waived by 
approval of Institutional Review Board. Between 2017 and 
2018, 38 patients at our institution received neoadjuvant 
therapy followed by radical esophagectomy and total 
lymphadenectomy for ESCC. The indication of neoadjuvant 
therapy for ESCC in our institution was clinical stage 
T1N1-2 or T2-4aN0-2 (AJCC 7 TNM classification). 
Among them, the patients who received conventional 
neoadjuvant chemoradiation therapy were assigned as 
Group 1, whereas the patients who received neoadjuvant 
chemoradiation therapy pembrolizumab were assigned as 
Group 2 (Figure 1). Neoadjuvant chemoradiation therapy 
with pembrolizumab was conducted as the single-arm, 
prospective phase II trial (Clinicaltrials.gov identifier: 
NCT02844075). Because the clinical trial was single-arm 
study, we retrospectively compared patients in Group 2 
with patients receiving conventional neoadjuvant CCRTx 
(Group 1) during the same study period. The inclusion 
criteria included in both groups were the same: (I) 
histologically or cytologically confirmed ESCC, (II) age 
≥20, (III) ECOG PS: 0–1, (IV) clinical stage T1N1-2 or 
T2-4aN0-2 (AJCC 7 TNM classification), (V) be willing 
to provide tissue from a newly obtained core or excisional 
biopsy of a tumor lesion through repeated biopsies, and (VI) 
adequate organ function.
Regimen of neoadjuvant therapy 
Patients enrolled in Groups 1 and 2 received a total 
radiation dose of 44.1 Gy with 21 fractions and 5 
fractions per week. The treatment in Group 1 consisted 
of continuous intravenous 5-fluorouracil 1,000 mg/body-
surface area (BSA) for 4 days, and cisplatin 75 mg/BSA for 
1 day every 4 weeks for two cycles in neoadjuvant period. 
The treatment in Group 2 included paclitaxel, carboplatin, 
and pembrolizumab. Paclitaxel at a dose of 45 mg/BSA and 
carboplatin targeted at an area under the curve of 2 mg per 
milliliter per minute were administered weekly for a total of 
5 doses along with pembrolizumab 200 mg every 3 weeks 
(total 2 doses). 
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Operation
The operation was done between 6 to 8 weeks after 
neoad juvant  therapy.  Esophagec tomy and  to ta l 
lymphadenectomy were done in all patients. Regarding the 
thoracic phase, minimally invasive esophagectomy, such as 
thoracoscopic or robotic esophagectomy, was the treatment of 
choice, but open thoracotomy was also performed in cases of 
T3 lesions or suspicious T4 lesions. Total lymphadenectomy, 
the complete dissection of the bilateral recurrent laryngeal 
nerve nodes, was performed in all patients. Neck dissection 
was performed when metastatic lymph nodes were suspected 
at the cervical area. Esophageal reconstruction was done with 
gastric tube and cervical anastomosis. After operation, the 
operating surgeon dissected the lymph nodes before sending 
the specimen to the pathologic department. 
Definition of complications and surgical outcomes
Postoperative complications were defined based on the 
Esophageal Complications Consensus Group (ECCG) 
criteria (5). In the ECCG criteria, pneumonia is defined as 
the presence of a new or progressive radiographic infiltrate 
plus at least two of three following clinical features: (I) fever 
greater than 38 ℃, (II) leukocytosis or leukopenia, or (III) 
purulent secretions. Acute respiratory distress syndrome 
(ARDS) was defined based on the Berlin definition (6). 
Vocal cords were routinely evaluated by the otolaryngologist 
to detect vocal cord palsy at postoperative day (POD) 7. 
The esophagography was done at POD 7 to evaluate the 
anastomotic integrity. The R0 resection was defined as 
negative resection margin as no cancer cells at the proximal, 
distal and circumferential margin. 
Statistical analyses
All observed data are presented as medians and interquartile 
range deviations for continuous variables and as frequencies 
and percentages for categorical variables. Groups 1 and 2 
Patients who received the 
esophagectomy for esophageal 





















Figure 1 Characteristics of patients enrolled in this study.
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were compared by the Kruskal-Wallis test or independent 
t-test for continuous variables according to the normality 
of the data and by the chi-square test or Fisher’s exact test 
for categorical variables. A two-sided P value of 0.05 was 
considered to indicate a statistically significant difference for 
all analyses. All statistical procedures were performed using 
R version 2.15.1 (R Foundation for Statistical Computing, 
Vienna, Austria).
Results
Patient and operative characteristics
Among 38 patients, 22 patients received conventional 
neoadjuvant chemoradiation therapy (Group 1), whereas 
16 patients received neoadjuvant chemoradiation therapy 
with pembrolizumab (Group 2, Figure 1). Basic clinical 
characteristics are described in Table 1. The mean age 
and sex were not different between the two groups. Open 
thoracotomy was more frequently performed in Group 1 
(45.5% vs. 18.8%, P=0.019). However, there were no 
thoracotomy conversion during the thoracoscopic and 
robotic esophagectomy in either group. Other variables 
such as clinical stage and neck dissection were not different 
between the two groups. Group 2 showed a higher ypStage 
pathologic stage than Group 1, but the difference was not 
statistically significant. 
The incidence of immune-related complications in Group 2
There were 1 hypothyroidism (grade 1) and 1 acneiform 
rash (grade 1) which were considered as immune-related 
Table 1 Patient basic characteristics 
Variables Group 1 (n=22) Group 2 (n=16) P
Age 61.50 (56.25–66.0) 58.5 (56.5–66.0) 0.962
Male 18 (81.8%) 13 (81.3%) 1.000
FEV1% 103 (95.25–109.0) 97.5 (89.5–113.0) 0.769
Clinical T stage 0.095
1/2/3/4 0/5 (22.7%)/16 (72.7%)/1 (4.5%) 4 (25%)/3 (18.8%)/8 (50%)/1 (6.3%)
Clinical N stage 0.485
0/1/2/3 2 (9.1%)/7 (31.8%)/12 (54.5%)/1 (4.5%) 2 (12.5%)/5 (31.3%)/6 (37.5%)/3 (18.8%)
Location 0.413
Upper 4 (18.2%) 4 (25.0%)
Middle 13 (59.1%) 6 (37.5%)
Lower 5 (22.7%) 6 (37.5%)
Type of thoracic approach 0.019
Open thoracotomy 10 (45.5%) 3 (18.8%)
VATS 3 (13.6%) 9 (56.3%)
Robot 9 (40.9%) 4 (25.0%)
Neck dissection 20 (90.9%) 15 (93.8%) 1.000
Pathologic stage 0.134
0 7 (31.8%) 1 (6.3%)
ypI 1 (4.5%) 0
ypII 8 (36.4%) 6 (37.5%)
ypIII 6 (27.3%) 9 (56.3%)
VATS, video-assisted thoracoscopic surgery
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in neoadjuvant period. We observed these two patients 
without specific medication such as thyroid hormone 
replacement or corticosteroid. And despite the immune-
related adverse events, all subjects had undergone pre-
planned R0 resection. In the adjuvant period, there were 8 
hepatitis (grade 1 or 2), one grade 1 hypothyroidism, and 
three grade 3 hypothyroidism. No serious adverse events 
or adverse events which led to treatment interruption or 
discontinuation occurred. Three subjects who experienced 
grade 3 hypothyroidism were managed with thyroid 
hormone replacement. All immune-related adverse events 
were manageable.
Operative outcomes
Regarding the postoperative outcomes, the operation time 
and blood loss were similar between the two groups (Table 2). 
The numbers of dissected lymph nodes were higher 
in Group 2 [53.5 (31–69.25) vs. 57 (4.25–74.25)], but 
differences were not statistically different (P=0.205). The 
numbers of dissected lymph nodes in neck, thorax, and 
abdomen were also similar. The numbers of left and right 
recurrent laryngeal nerve nodes were also comparable. The 
numbers of positive lymph nodes were higher in Group 2 
than in Group 1 [1 (0–2.25) vs. 2 (1–4)], but they were 
statistically marginal (P=0.085). All patients received the R0 
resection. 
The operative complications are summarized in Table 3. 
The incidence of ARDS was higher in Group 2 than in 
Group 1 (18.8% vs. 4.5%), but it was not statistically 
different (P=0.291). The incidences of other complications 
such as recurrent laryngeal nerve palsy and anastomotic 
leakage were also similar. All anastomotic leakage was 
ECCG grade II. In-hospital mortalities occurred in 
Group 2. The length of hospital stay was not statistically 
different between the two groups, but they tended to be 
longer in Group 2 (22.45±15.09 vs. 41.19±45.59 days, 
P=0.132). 
Two cases of operative mortality occurred in Group 2. 
The first case was a 62 years old male patient. He 
underwent an open esophagectomy and total mediastinal 
lymph node dissection, three field lymph node dissection, 
and cervical esophagogastrostomy. At POD 2, bilateral 
infiltration developed in his lower lung field and ARDS was 
diagnosed based on the PaO2/FiO2 ratio. He did not recover 
from the ARDS and died at POD 146.
The second case was a 72-year-old male patient 
with underlying pulmonary emphysema. He received a 
thoracoscopic esophagectomy and total mediastinal lymph 
node dissection, three field lymph node dissections, and 
a cervical esophagogastrostomy. At POD 6, bilateral 
infiltration was detected on chest X-ray, and a chest CT 
showed bilateral diffuse ground glass opacity and interlobar 
septal thickening (Figure 2A,B). He received medical 
treatment including steroid pulse therapy and empirical 
antibiotics, but he died at POD 51.
Discussion
Immune checkpoint inhibitors have recently been 
Table 2 Operative outcomes
Variables Group 1 (n=22) Group 2 (n=16) P
Operation time (minutes) 309 (348–438.5) 365.5 (332.5–418.5) 0.338
Blood loss (mL) 225 (150–362.5) 225 (162.5–430) 0.420
Numbers of total dissected LNs 53.5 (31–69.25) 57 (45.25–74.25) 0.205
Numbers of positive LNs 1 (0–2.25) 2 (1–4) 0.085
Numbers of dissected LNs in thorax 17.5 (14–30) 23.5 (17.5–30.5) 0.626
Numbers of dissected LNs in Rt. RLNs 3.5 (1–5) 3.5 (1–4.75) 0.535
Numbers of dissected LNs in Lt. RLNs 2.5 (1–6) 2 (1–5) 0.491
Numbers of dissected LNs in neck 12 (8–25.25) 18 (13–28.5) 0.130
Numbers of dissected LNs in abdomen 12 (8–21.25) 17 (11.25–20) 0.807
Hospital Stay (days) 16 (13–26.5) 19 (15.25–49.75) 0.132
LN, lymph node; RLN, recurrent laryngeal nerve.
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highlighted in the field of thoracic malignancy. The 
results from a phase II clinical trial of nivolumab for 
ESCC (4), in which 64 patients with ESCC who were 
refractory or intolerant to standard chemotherapy, 
including 5-fluorouracil,  CDDP, and Taxan-based 
regimens, showed a complete or partial response in 14% of 
patients, and a disease control ratio was observed in 42%. 
Moreover, the profile for adverse events was acceptable 
and manageable.  Also,  the KEYNOTE-181 study 
reported that pembrolizumab significantly improved OS 
compared with chemo as second-line therapy for advanced 
esophageal cancer with PD-L1 combined positive score 
≥10, accompanied by a more favorable safety profile (7). 
Based on these results, our group conducted a phase II trial 
of neoadjuvant CCRTx with pembrolizumab for ESCC; 
our results discussing the feasibility, safety and effectiveness 
of neoadjuvant therapy will be published separately. In 
the current paper, we focused on the operative outcomes 
for neoadjuvant CCRTx with Pembrolizumab, especially 
compared with conventional neoadjuvant CCRTx. 
Neoadjuvant therapy has many potential advantages in 
esophageal cancer treatment. The CROSS trial showed the 
Table 3 Postoperative complications
Variables Group 1 (n=22) Group 2 (n=16) P
All complications 13 (59.1%) 11 (68.7%) 0.735
Acute respiratory distress syndrome 1 (4.5%) 3 (18.8%) 0.291
Recurrent laryngeal nerve palsy 7 (31.8%) 3 (18.8%) 0.469
Type I 5 (22.8%) 3 (18.8%)
Type II 2 (9.1%) 0
Anastomotic leakage 3 (13.6%) 3 (18.8%) 0.682
Type II 2 (9.1%) 3 (18.8%)
Type III 1 (4.5%) 0
Chyloperitoneum 1 (4.5%) 0 1.000
Wound infection 0 1 (6.3%) 0.421
Atrial dysrhythmia 0 1 (6.3%) 0.421
Ileus 1 (4.5%) 0 1.000
Operative mortality 0 2 (12.5%) 0.171
Figure 2 Chest CT findings of mortality case. The bilateral diffuse ground glass opacity and interlobar septal thickening developed in both 
lung fields. (A) Middle lung field. (B) Lower lung fields.
BA
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overall survival benefits for neoadjuvant chemoradiotherapy 
when added to surgery in patients with resectable 
esophageal or esophagogastric junctional cancer, especially 
in ESCC (8). The JCOG 9907 trial determined that 
preoperative chemotherapy with cisplatin plus 5-fluorouracil 
followed by surgery showed survival benefits compared with 
surgery followed by adjuvant therapy (9). In the viewpoint 
of surgeons, one of the most important concerns regarding 
neoadjuvant therapy is that the neoadjuvant therapy itself 
should not worsen the quality and surgical outcomes of 
any given operation. After preoperative immunotherapy, 
fibrosis around the tumor and tumor microenvironment 
are frequently reported (10). The initial retrospective 
case series in patients who received pulmonary resection 
for previously unresectable or metastatic non-small cell 
lung cancer suggest overall feasibility but have also raised 
concerns about technical challenges and perioperative issues 
unique to this patient population (10). Especially the radical 
esophagectomy including the dissection along the bilateral 
recurrent laryngeal nerve is the mainstay of treatment in 
ESCC, and we think that meticulous dissection, especially 
along the recurrent laryngeal nerve nodes, is an important 
procedure even after neoadjuvant therapy. Therefore, we 
were concerned that the quality of lymph node dissection 
might be decreased if immunotherapy was added in 
addition to CCRTx. In contrast to our initial assumption, 
dissection along the recurrent laryngeal nerve was feasible 
and safe in Group 2, and we could maintain our radical 
surgical strategies (Figure 3A,B). The numbers of dissected 
lymph nodes along the recurrent laryngeal nerve were 
comparable between two groups, and the incidence of vocal 
cord palsy, which can develop after recurrent laryngeal 
nerve dissection, was not statistically different between 
the two groups. These results imply that the preoperative 
immunotherapy did not decrease the quality of radial 
esophagectomy. In addition, the other major complication, 
anastomotic leakage, developed similarly in both groups. 
The longer hospital stays for Group 2 was might be related 
to the operative mortality cases, even though it was not 
statistically significant.
Even though it was not statistically significant, the 
incidence of ARDS was higher in Group 2 (18.8% vs. 4.5%, 
P=0.291). Moreover, two patients showed operative mortality 
in Group 2. While the toxicity profile of immunotherapy 
is favorable compared with traditional cytotoxic therapy, 
the  immune boost ing mechanism of  monoclonal 
antibodies can produce severe autoimmune adverse 
effects such as pneumonitis, arthralgia, pyrexia, colitis, 
dermatitis, hepatitis, endocrinopathy, and neuropathy (11). 
Large meta-analyses of randomized trials and retrospective 
studies using anti-PD1 and PDL1 antibodies across 
melanoma, lung cancer, and renal cancer found an overall 
incidence of pulmonary toxicity of 2.7–3.5% (12). It has 
been reported that the immune-related adverse events, 
including pulmonary toxicities, might occur at any point 
during treatment, and who will develop these toxicities 
or how long they will last is unclear (13). Pathologically, 
80% of immune check-point inhibitor related pulmonary 
toxicities are T-lymphocytic alveolitis (13). Especially, it 
has been reported that the combination of radiotherapy 
with immunotherapy increased the risk of pulmonary 
toxicity when compared with the historical incidence of 
pulmonary toxicity with immunotherapy alone (14). In our 
series, two patients who received neoadjuvant CCRTx with 
Figure 3 The radical dissection of bilateral recurrent laryngeal nerve lymph nodes after the neoadjuvant chemoradiation with 
immunotherapy. (A) Right recurrent laryngeal nerve lymph nodes. (B) Left recurrent laryngeal nerve lymph nodes.
BA
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immunotherapy died of pulmonary complications. It is 
possible that these pulmonary complications may be related 
to the immune check-point inhibitor associated pulmonary 
toxicities. However, acute lung injury also develops 
frequently after esophagectomy; the incidence of pulmonary 
complications including ARDS after esophagectomy in 
high-volume centers may exceed 20% (15). It is unclear 
whether the causes of ARDS in our patients were related to 
the immunotherapy or not. Therefore, further research is 
needed to determine whether the combination of CCRTx 
and immunotherapy is feasible, because of the potential 
synergistic effects of CCRTx and immunotherapy, especially 
after esophagectomy
In regard to immune-related adverse events, the median 
follow-up period of pembrolizumab arm was 18.3 months 
at the data cutoff and the incidence of immune-related 
hepatitis and hypothyroidism were 50% and 25%, 
respectively and these numbers were higher compared to 
major clinical trials (4,7). However, these events were all 
asymptomatic and the administration of pembrolizumab 
was not interrupted or delayed. Also, there were no serious 
adverse events and immune-suppressive treatment such as 
corticosteroid was not required at all. There was no new 
safety signal and the reported higher number of immune-
related adverse events may be attributable to the small 
sample size of the study.
This study has several limitations. First, this study is a 
retrospective study without randomization. Even though 
there was no statistical significance, Group 2 showed both 
higher clinical stage and higher pathologic stage (higher 
numbers of positive lymph nodes) outcomes. In Group 1, 
the esophagectomy under open thoracotomy was more 
frequently performed based on the surgeon’s preferences. 
Second, the regimens of CCRTx were different between 
two groups. In South Korea, 5-fluororacil and cisplatin 
for esophageal cancer has been approved and reimbursed, 
but paclitaxel and carboplatin are not. Therefore Group 1 
received infusional 5FU/cisplatin under the reimbursement 
and Group 2 patients could receive paclitaxel/carboplatin 
under the clinical trial. The purpose of this study was to 
compare the surgical outcomes, so the different CCRTx 
regimens might not be problematic. Third, the number of 
patients was small, so the further study has to be done with 
large numbers of patients with randomization. However, 
the we maintained uniform, radical surgical strategies in all 
patients. To our knowledge, this study is the first to report 
the surgical outcomes of neoadjuvant immunotherapy 
in ESCC. To overcome the limitations of this study, a 
randomized study with large numbers of patients is needed 
in the future. 
In conclusion, radical esophagectomy for esophageal 
squamous cell carcinoma after neoadjuvant chemoradiation 
therapy with immune checkpoint inhibitors might not 
increase the operative risk or reduce the quality of radical 
dissection including lymphadenectomy.
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